Core Viewpoint - Nanobiotix has issued a statement denying any intentions for a public takeover, addressing recent media speculation and highlighting inaccuracies in the reports [1][2]. Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on pioneering nanotherapeutic approaches to enhance treatment options for cancer and other significant diseases [1][3]. - The company was incorporated in 2003, is headquartered in Paris, France, and has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020 [4]. - Nanobiotix owns over 30 umbrella patents related to three nanotechnology platforms, which have applications in oncology, bioavailability and biodistribution, and central nervous system disorders [5].

Core Viewpoint - Nanobiotix, a late-stage clinical biotechnology company, is set to participate in several upcoming healthcare conferences in March 2026, showcasing its innovative nanotherapeutic approaches for cancer and other major diseases [1][2]. Company Overview - Nanobiotix was incorporated in 2003 and is headquartered in Paris, France. It has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020. The company has subsidiaries in Cambridge, Massachusetts, among other locations [3]. - The company owns over 25 patent families related to three nanotechnology platforms, which have applications in oncology, bioavailability and biodistribution, and disorders of the central nervous system [3]. Upcoming Conferences - Nanobiotix will present at the following conferences: - TD Cowen's Health Care Conference on March 4, 2026, in Boston, MA, with a fireside chat at 11:10 am ET [1]. - UBS Biotech Summit on March 9, 2026, in Miami Beach, FL [2]. - Jefferies Biotech on the Beach Summit on March 10, 2026, in Miami Beach, FL [2]. - Leerink's Global Healthcare Conference on March 11, 2026, in Miami Beach, FL, with a fireside chat at 2:20 pm EDT [2]. - Presenters at these events will include Laurent Levy, CEO, and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix [1][2].

Core Insights - Nanobiotix presented full results from a Phase 1 study of JNJ-1900 (NBTXR3) for locally advanced or borderline resectable pancreatic cancer at the 2025 ESTRO Annual Meeting [1][3] - The study showed promising safety and efficacy outcomes, indicating a potential new treatment option for patients with high unmet needs in this area [5][9] Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on innovative nanotherapeutic approaches to enhance cancer treatment outcomes [15][16] - The company is headquartered in Paris, France, and is listed on Euronext Paris and NASDAQ [16] Study Details - The Phase 1 study evaluated JNJ-1900 (NBTXR3) activated by radiotherapy in patients with locally advanced or borderline resectable pancreatic cancer, replacing standard concurrent chemoradiation [3][6] - The study was conducted by The University of Texas MD Anderson Cancer Center, with Dr. Eugene Koay as the principal investigator [1][3] Key Results - The study involved 22 patients, with a median overall survival of 23 months from diagnosis and a median local progression-free survival of 13.3 months from completion of radiation [5][6] - Notable findings included a 59% normalization rate of CA19-9, a biomarker associated with overall survival, and an association between increased circulating tumor mutational burden (cTMB) and improved survival outcomes [5][12] Future Directions - Investigators concluded that further evaluation of JNJ-1900 (NBTXR3) is warranted in a randomized study, with ongoing recruitment for a new cohort combining JNJ-1900 with standard-of-care concurrent chemotherapy [8][9] - The collaboration with MD Anderson aims to explore innovative treatment approaches for patients with high unmet needs in pancreatic cancer [9][14]